---
title: "Cullinan unit ends MIT license for CLN-617"
url: "https://aibio.space/news/cullinan-unit-ends-mit-license-cln-617-after-dropping-program/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-11-21"
section: "Distress"
tickers: "NASDAQ:CGEM"
source: "https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/cgem-20251118.htm"
summary: "Cullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026."
---

By the aibio.space news desk.

Sources

- [Cullinan Therapeutics, Inc. 8-K (2025-11-21)](https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/cgem-20251118.htm)

[CGEM](https://aibio.space/companies/cullinan-therapeutics/)

2025-11-21

# Cullinan unit ends MIT license for CLN-617 after dropping the program

Tickers [CGEM](https://aibio.space/companies/cullinan-therapeutics/)

Cullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026.

## Key facts

- **Company**: Cullinan Therapeutics, Inc. (NASDAQ: CGEM)

- **News type**: Distress

- **Primary source**: [Cullinan Therapeutics, Inc. 8-K (2025-11-21)](https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/cgem-20251118.htm)

*The Capitol dome seen from below. Photo: U.S. Department of Homeland Security (Source), CC0, via rawpixel. The picture shows the field, not the companies named.*

Cullinan Amber Corp., a subsidiary of Cullinan Therapeutics, Inc. ([CGEM](https://aibio.space/companies/cullinan-therapeutics/)), notified the Massachusetts Institute of Technology (MIT) on November 18, 2025 that it is ending its Exclusive Patent License Agreement. The agreement is dated December 20, 2019, and has been amended from time to time. The termination is effective as of February 18, 2026.

The company took the step in connection with its decision not to pursue further development of CLN-617. Under the license, MIT had granted the company exclusive worldwide rights to the technology underlying CLN-617, so that it could develop a cancer immunotherapy product worldwide. The 8-K was filed on November 21, 2025.

As part of the termination, the company will return the licensed patent rights for the technology underlying CLN-617 to MIT.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

CGEM

Cullinan Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/cullinan-unit-ends-mit-license-cln-617-after-dropping-program/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cullinan unit ends MIT license for CLN-617", 2025-11-21, https://aibio.space/news/cullinan-unit-ends-mit-license-cln-617-after-dropping-program/